首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
【24h】

Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.

机译:恶性胸膜间皮瘤开放式保肺手术:多种治疗方法中根治方法的好处。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP). METHODS: We reviewed 102 consecutive patients (93 male; 9 female, mean age 63 years) who were not suitable for EPP because of either advanced tumour stage or suboptimal fitness. Patients underwent either a non-radical tumour decortication to obtain lung expansion (group NR) or latterly a radical pleurectomy/decortication to obtain macroscopic tumour clearance (group R). We analysed the comparative perioperative courses and long-term survival. RESULTS: The two groups were similar for age and gender distribution but epithelioid type was more predominant in group R: 78% compared to 55% epithelioid in group NR. Thirty-day mortality was similar (5.9% in group R and 9.8% in the group NR, p=0.36) but 90-day mortality was significantly higher in the group NR (29.4% vs 9.8% in group R, p=0.012). More patients in group R received adjuvant chemotherapy (65% vs 28%, p=0.000) and radiotherapy (65% vs 26%, p=0.000). Median survival for all cell types was significantly higher in group R (15.3 months vs 7.1 months, p<0.000). Group R survival rates at 1, 2, 3 and 4 years were 53, 41, 25 and 13%, respectively while for group NR they were 32, 9.6, 2 and 0%, respectively. For epithelioid cell type there was still a significant median survival advantage in group R (25.4 months vs 10.2 months, p<0.000), but there was no difference for sarcomatoid (9.3 months vs 3.2 months, p=0.16) or biphasic cell types (9.4 months vs 7 months, p=0.38). CONCLUSION: If a patient with epithelioid MPM is fit enough to tolerate a thoracotomy then macroscopic clearance of the tumour is the preferred option as part of a multimodality regime including chemotherapy.
机译:目的:确定不适合胸膜外肺切除术(EPP)的恶性胸膜间皮瘤患者的最佳减体程序。方法:我们回顾了102例因肿瘤晚期或适应性欠佳而不适合EPP的患者(男93例,女9例,平均年龄63岁)。患者接受非根治性肿瘤去皮术以扩大肺部(NR组),或随后接受根治性胸膜切除术/去皮屑以获得宏观肿瘤清除率(R组)。我们分析了比较的围手术期和长期生存。结果:两组在年龄和性别分布上相似,但R组中上皮样类型更占优势:78%相比NR组中上皮样类型为55%。 30天死亡率相似(R组为5.9%,NR组为9.8%,p = 0.36),但NR组90天死亡率显着较高(R组为29.4%,而9.8%,p = 0.012) 。 R组中更多的患者接受了辅助化疗(65%vs 28%,p = 0.000)和放疗(65%vs 26%,p = 0.000)。 R组中所有细胞类型的中位生存期均显着更高(15.3个月对7.1个月,p <0.000)。 R组在1、2、3和4年的生存率分别为53%,41%,25%和13%,而NR组的分别为32%,9.6%,2%和0%。对于上皮样细胞类型,R组仍具有显着的中位生存优势(25.4个月对10.2个月,p <0.000),但对于肉瘤样样细胞(9.3个月对3.2个月,p = 0.16)或双相细胞类型没有显着差异( 9.4个月vs 7个月,p = 0.38)。结论:如果上皮样MPM患者足够适合耐受开胸手术,那么从宏观上清除肿瘤是作为包括化疗在内的多模式治疗方案的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号